Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Renal Response News

Renal Response News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Renal Response. Real-time updates on events, politics, business and more.

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis

May 3, 2023
Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis ... | May 3, 2023
United States United Kingdom Great Britain Peter Greenleaf Healthcare Products Regulatory Agency Aurinia Pharmaceuticals Inc
Source: marketscreener.com

Aurinia Pharmaceuticals Inc.: Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS (Voclosporin) For Adults with Active Lupus Nephritis

May 3, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option
United States United Kingdom Great Britain Peter Greenleaf Aurinia Pharmaceuticals National Institute For Health
Source: finanznachrichten.de

Otsuka announces MHRA authorisation of Lupkynis® (voclosporin) as first oral calcineurin-inhibitor ▼ (CNI) for active lupus nephritis

December 1, 2022
Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus ...
United Kingdom Northern Ireland City Of Great Britain Otsuka Europe Ryan Gynne
Source: pharmiweb.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science